|
Italy Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Italy Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Italy.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Italian pharmaceutical and healthcare industry.
Competitive intelligence, Italian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Italian market.
The Italy Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Italy Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Italian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Italy to test other views – a key input for successful budgeting and strategic business planning in the Italian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Italian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Italy.
- Exploit The Latest Competitive Italian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Italy.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Italy Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Table: Italy Pharmaceuticals And Healthcare Industry SWOT |
| Italy Political SWOT |
| Italy Economic SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Italy - Market Summary |
| Regulatory Regime |
| Table: Italy - Examples of Pharmaceutical Status Switches |
| Recent EU-Wide Regulatory Developments |
| Table: Adherence Mandatory: H108 |
| Intellectual Property Developments |
| Counterfeit Pharmaceuticals |
| Pricing Regime |
| Price Cuts |
| Reimbursement Regime |
Chapter - Industry Developments |
| Epidemiology |
| Table: Disease Burden In Western Europe |
| Healthcare Sector |
| Healthcare Financing |
| Pharmaceutical Industry |
| Recent Company Developments |
| Wholesale Sector |
| Retail Pharmacy Sector |
| Biotechnology |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Italy - Drug Market Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Italy - Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Italy - Economic Activity |
| Prescription Market Forecast |
| Top 10 Active Pharmaceutical Ingredients By SSN Expenditure |
| Table: Italy - Prescription Market Indicators, Historical Data and Forecasts (EURmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Italy – Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Italy - Generics Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Italy - OTC Market Indicators, Historical Data and Forecasts (EURmn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: Italy - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Medical Devices Forecasts |
| Table: Italy - Medical Device Market, , Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Italy – Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risk To BMI's Forecasts |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Multinational Manufacturers |
| GlaxoSmithKline |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Indigenous Manufacturer |
| Recordati |
Chapter - Country Snapshot: Italy Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Italy Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Italian economy is one of the most vulnerable economies in an already shaky eurozone. High public debt, poor infrastructure, and a lack of competitiveness are the basis for the likelihood that the country will remain on the region's laggards over our forecast period. Additionally, low levels of growth of the Italian pharmaceutical market, which have come about largely as a result of widespread price cuts, mean that Italy now sits third from the bottom of our Business Environment Rankings for Western Europe in Q209. Despite this, the sheer size of Italy's drug market (at US$30.7bn in 2008) and the recently announced improvements to its regulatory agency mean that Italy is the 14th most attractive pharmaceutical market in global terms. By 2013, however, its compound annual growth rate (CAGR) will be negative in US dollar terms (with the market value at consumer prices falling to US$29.9bn), as the government continues its cost-containment drive.
In addition, manufacturers have raised the issue of limited access to innovation – with regional variations a key problem. Research-based companies have complained that incessant price cuts are resulting in fewer funds available for research and development (R&D) activities. Pfizer, the leading global pharmaceutical company, sold its Italian manufacturing plant in Nerviano to Icelandic generics company Actavis at the start of 2008, only to announce a major cut in the number of its sales jobs in Italy a year later. Both developments are clear indications of the difficult operating conditions in the country’s pharmaceutical market, with Pfizer additionally facing a major European patent expiration in 2011.
Nevertheless, pharmaceutical manufacturers are certain to welcome some of the recent regulatory developments. For example, in January 2009, the Italian parliament began considering a revision of the economic stimulus bill. The changes would reserve US$23.73mn per annum for the provision of financial assistance to families that have new-born children suffering from any one of 6,000 rare diseases. Around the same time, Spanish pharmaceutical company PharmaMar announced that its designated orphan drug for the treatment of soft tissue sarcomas and ovarian cancer – Yondelis (trabectedin) – had received approval for price and reimbursement from Italian authorities.
In what can be seen as a welcome development for the pharmacy retail sector, the European Commission recently appealed to the Italian government to modify legislation that limits the ownership of multiple retail pharmacies. The commission stated that if the Italian restrictions are not changed within two months, the next step would be the involvement of the European Court of Justice (ECJ). According to existing provisions, a pharmacy chain can have a maximum of four outlets within the country's 108 provinces, which is in conflict with free trading in Article 43 of the European Community Treaty.
|
Italy Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |